TY - JOUR
T1 - Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy
AU - Kongtim, Piyanuch
AU - Lee, Dean A.
AU - Cooper, Laurence J.N.
AU - Kebriaei, Partow
AU - Champlin, Richard E.
AU - Ciurea, Stefan O.
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Haploidentical transplantation can extend the opportunity for transplantation to almost all patients who lack an HLA-matched donor. Advances in the field of haploidentical transplantation have led to a marked decrease in treatment-related mortality, allowing investigators to focus on developing rationale pre- and peri-remission therapies aimed at preventing disease relapse after transplantation. Because of widespread availability, low treatment-related mortality, and cost, haploidentical donors may become the preferred "alternative" donors for allogeneic hematopoietic stem cell transplantation. One of the major advantages of using a related donor is the possibility of collecting or generating additional cellular products from the same immediately available donor, which will not be rejected. Infusion of these cells in the peri-transplantation period, derived from the same immune system, is opening the possibility of markedly enhancing the antitumor effects of the graft and hastening immunologic reconstitution after transplantation.
AB - Haploidentical transplantation can extend the opportunity for transplantation to almost all patients who lack an HLA-matched donor. Advances in the field of haploidentical transplantation have led to a marked decrease in treatment-related mortality, allowing investigators to focus on developing rationale pre- and peri-remission therapies aimed at preventing disease relapse after transplantation. Because of widespread availability, low treatment-related mortality, and cost, haploidentical donors may become the preferred "alternative" donors for allogeneic hematopoietic stem cell transplantation. One of the major advantages of using a related donor is the possibility of collecting or generating additional cellular products from the same immediately available donor, which will not be rejected. Infusion of these cells in the peri-transplantation period, derived from the same immune system, is opening the possibility of markedly enhancing the antitumor effects of the graft and hastening immunologic reconstitution after transplantation.
KW - Alpha-beta T cell depletion
KW - Cellular therapy
KW - Chimeric antigen receptor T cells
KW - Donor lymphocyte infusion
KW - Haploidentical transplantation
KW - Natural killer cells
KW - Post-transplantation cyclophosphamide
UR - http://www.scopus.com/inward/record.url?scp=84941285164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941285164&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2015.07.002
DO - 10.1016/j.bbmt.2015.07.002
M3 - Review article
C2 - 26172479
AN - SCOPUS:84941285164
SN - 1083-8791
VL - 21
SP - 1714
EP - 1720
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 10
ER -